Rowan Walrath

2 weeks ago | cen.acs.org | Rowan Walrath

The last few weeks have been busy for Jim Corbett. Corbett, the CEO of organ-chip developer Emulate, has been fielding requests from potential clients, as well as from early investors who say they want to put more money into the start-up. The impetus: an announcement from the US Food and Drug Administration in early April indicating that the agency plans to phase out animal tests -a longtime cornerstone of preclinical drug testing-in favor of other technologies.

2 weeks ago | pubs.acs.org | Rowan Walrath

Monday, May 12, 2025 Please be aware that pubs.acs.org is undergoing maintenance from Saturday February 1 to Monday Febraury 3, that may have an impact on your experience. During this time, you may not be able to access certain features like login, purchasing single articles, saving searches or running existing saved searches, modifying your e-Alert preferences, or accessing Librarian administrative functions. We appreciate your patience as we continue to improve the ACS Publications platform.

3 weeks ago | cen.acs.org | Rowan Walrath

Flagship Pioneering has unveiled a new start-up that aims to find, then drug, targets that are specific to different states of diseases. The company, Etiome, will begin with metabolic, neurodegenerative, and inflammatory illnesses. The venture firm has backed Etiome with $50 million, enough to give the start-up about a year and a half of runway, says Etiome cofounder and president Scott Lipnick, who also serves as an origination partner in Flagship's Preemptive Health and Medicine Initiative.

1 month ago | cen.acs.org | Laurel Oldach |Krystal Vasquez |Rowan Walrath

She was excited when the acceptance letter came in January, from a research university in a major East Coast city. "In my brain, I was like, 'Yeah, this is it,' " the student tells C&EN. But in February, when she put together all the offers she had, she began to feel nervous. The offer letter from the research university that was her first choice had promised a contract to follow, but it hadn't yet arrived.

1 month ago | cen.acs.org | Rowan Walrath

At UMass Chan Medical School, gene therapy researchers Terence R. Flotte and Robert H. Brown are trying to figure out how to treat amyotrophic lateral sclerosis, the fatal neurodegenerative condition better known as ALS or Lou Gehrig's disease. They've made some progress: antisense oligonucleotides were able to slow down disease progression in at least one patient, and other studies from their labs have helped pin down some genetic causes of the disease, which is still poorly understood.